| A meta-analysis of GFR slope as a surrogate endpoint for kidney failure | 37330614 | | Journal | 2023 | 10.1038/s41591-023-02418-0 | HALT PKD, FONT II, FSGS/FONT | 22864, 23584 | Secondary Research |
| ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing | 29203126 | PMC6267804 | Journal | 2018 | 10.1053/j.ajkd.2017.09.008 | HALT PKD | 20790 | Secondary Research |
| Acute treatment effects on GFR in randomized clinical trials of kidney disease progression. | 34862238 | PMC8819983 | Journal | 2022 | 10.1681/ASN.2021070948 | HALT PKD | 21181 | Secondary Research |
| Baseline total kidney volume and the rate of kidney growth are
associated with chronic kidney disease progression in Autosomal Dominant
Polycystic Kidney Disease | 29290310 | PMC5826779 | Journal | 2017 | 10.1016/j.kint.2017.09.027 | HALT PKD | 20790 | Secondary Research |
| CD8+ T cells modulate autosomal dominant polycystic kidney disease progression | 30249452 | PMC6319903 | Journal | 2018 | 10.1016/j.kint.2018.06.025 | HALT PKD | 20959 | Secondary Research |
| Change in albuminuria and GFR slope as joint surrogate endpoints for kidney failure - Implications for phase 2 clinical trials in chronic kidney disease | 36918388 | | Journal | 2023 | 10.1681/ASN.0000000000000117 | HALT PKD | 21181 | Secondary Research |
| Collagen IV Gene Mutations in Adults With Bilateral Renal Cysts and CKD | 31922066 | PMC6943786 | Journal | 2019 | 10.1016/j.ekir.2019.09.004 | HALT PKD | 21532, 21588, 21748 | Secondary Research |
| Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease. | 31874800 | PMC7218796 | Journal | 2020 | 10.1016/j.kint.2019.08.038 | HALT PKD | 20790, 20959, 21225, 21507, 22080 | Secondary Research |
| Development of a Clinical Trial Enrichment (CTE) Tool for Autosomal Dominant Polycystic Kidney Disease | | | Conference Presentation | 2023 | | HALT PKD, CRISP | 22905 | Secondary Research |
| Effects of Tolvaptan on Kidney Function Decline in Patients Aged >55 Years With Autosomal Dominant Polycystic Kidney Disease: Pooled Data Analysis | 37250503 | PMC10220412 | Journal | 2023 | 10.1016/j.xkme.2023.100639 | HALT PKD, CRISP | 21540 | Secondary Research |
| Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD) | 29401581 | PMC5901382 | Journal | 2018 | 10.1096/fj.201700909R | HALT PKD | 21532, 21588 | Secondary Research |
| Impact of early glomerular filtration rate decline in
response to antihypertensive treatment on risk of
end-stage kidney disease and cardiovascular outcomes:
a systematic review and meta-analysis | 34930868 | | Journal | 2022 | 10.1097/HJH.0000000000003066 | HALT PKD | 23180 | Secondary Research |
| Interactions between FGF23 and Genotype in Autosomal Dominant Polycystic Kidney Disease. | 33305291 | PMC7725226 | Journal | 2020 | 10.34067/KID.0001692020 | HALT PKD | 20790, 20959 | Secondary Research |
| KIDNEY FUNCTION DECLINE IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE PATIENTS: ASSESSMENT OF TOLVAPTAN'S REAL WORLD EFFECTIVENESS | | | Conference Presentation | 2023 | | HALT PKD, CRISP | 21540 | Secondary Research |
| KIM-1 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease: HALT-PKD Results. | 32541154 | PMC7384479 | Journal | 2020 | 10.1159/000508051 | HALT PKD | 20959, 22080 | Secondary Research |
| Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease. | 30922668 | PMC6478515 | Journal | 2019 | 10.1016/j.kint.2018.12.023 | HALT PKD | 20790 | Secondary Research |
| Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease. | 29854969 | PMC5976807 | Journal | 2018 | 10.1016/j.ekir.2017.12.011 | HALT PKD | 20790 | Secondary Research |
| Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype. | 34890546 | PMC8764120 | Journal | 2022 | 10.1016/j.ajhg.2021.11.016 | HALT PKD | 21225 | Secondary Research |
| Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease. | 27259053 | PMC4908191 | Journal | 2016 | 10.1016/j.ajhg.2016.05.004 | HALT PKD | 20790, 21225 | Secondary Research |
| Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. | 29118087 | PMC5791072 | Journal | 2018 | 10.1681/ASN.2017070819 | HALT PKD | 20790, 20959 | Secondary Research |
| Overweight and Obesity and Progression of ADPKD | 34117082 | PMC8216617 | Journal | 2021 | 10.2215/CJN.16871020 | HALT PKD | 20959, 22080 | Secondary Research |
| POOLED DATA ANALYSIS OF THE EFFECT OF TOLVAPTAN IN PATIENTS AGED 18-35 YEARS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE | 35570988 | PMC9091612 | Conference Presentation | 2023 | 10.1016/j.ekir.2022.02.009 | HALT PKD, CRISP | 21540 | Secondary Research |
| Pain and Obesity in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis of the Halt Progression of Polycystic Kidney Disease (HALT-PKD) Studies. | 34401721 | PMC8350824 | Journal | 2021 | 10.1016/j.xkme.2021.03.004 | HALT PKD | 20790, 20959, 22080 | Secondary Research |
| Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course. | 30803434 | PMC6388487 | Journal | 2019 | 10.1186/s12882-019-1249-6 | HALT PKD | 20790, 21328 | Secondary Research |
| Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease. | 26823553 | PMC5004648 | Journal | 2016 | 10.1681/ASN.2015050583 | HALT PKD | 20790 | Secondary Research |
| The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD. | 36204243 | PMC9529969 | Journal | 2022 | 10.1016/j.xkme.2022.100538 | HALT PKD | 20790, 20997 | Secondary Research |
| The Value of Genetic Testing in Polycystic Kidney Diseases Illustrated by a Family With PKD2 and COL4A1 Mutations. | 29395486 | PMC6057824 | Journal | 2018 | 10.1053/j.ajkd.2017.11.015 | HALT PKD | 21225, 21507 | Secondary Research |
| The tryptophan-metabolizing enzyme indoleamine 2,3-dioxygenase 1 regulates polycystic kidney disease progression | 36422996 | PMC9870090 | Journal | 2023 | 10.1172/jci.insight.154773 | HALT PKD | 20959, 22080 | Secondary Research |
| The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD. | 32634120 | PMC7455088 | Journal | 2020 | 10.1172/jci.insight.138724 | HALT PKD | 20790 | Secondary Research |
| Tolvaptan and Kidney Function Decline in Older Individuals With Autosomal Dominant Polycystic Kidney Disease: A Pooled Analysis of Randomized Clinical Trials and Observational Studies. | 37250503 | PMC10220412 | Journal | 2023 | 10.1016/j.xkme.2023.100639 | HALT PKD | 21540 | Secondary Research |
| Vascular Dysfunction, Oxidative Stress, and Inflammation in Autosomal Dominant Polycystic Kidney Disease | 30228110 | PMC6218833 | Journal | 2018 | 10.2215/CJN.05850518 | HALT PKD | 20959 | Secondary Research |
| Volume Progression and Imaging Classification of Polycystic Liver in Early Autosomal Dominant Polycystic Kidney Disease. | 35217526 | PMC8975034 | Journal | 2022 | 10.2215/CJN.08660621 | HALT PKD | 20790 | Secondary Research |
| Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease | 35059607 | PMC8760407 | Journal | 2021 | 10.1016/j.isci.2021.103697 | HALT PKD | 20959, 22080 | Secondary Research |
| An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International | 35134221 | PMC9035348 | Journal | 2022 | 10.1093/ndt/gfab312 | HALT PKD | 21225 | Secondary Research |
